Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
2.090
+0.100 (5.03%)
At close: Aug 27, 2025, 4:00 PM
2.050
-0.040 (-1.91%)
After-hours: Aug 27, 2025, 7:45 PM EDT
Citius Oncology Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Citius Oncology.
Price Target: $ (0.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Citius Oncology is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 23, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +43.54% | Nov 27, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +187.08% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
74.34M
EPS This Year
-0.49
from -0.31
EPS Next Year
0.05
from -0.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 76.5M | |
| Avg | n/a | 74.3M | |
| Low | n/a | 71.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.50 | 0.05 | |
| Avg | -0.49 | 0.05 | |
| Low | -0.47 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.